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Introduction
The Amyloidoses Associated with Transthyretin (ATTR) 
are autosomal-dominant diseases related to at least 100 different 
Transthyretin (TTR) mutations. The single amino-acid substitution of 
methionine for valine at position 30 is the most common [1]. Although 
this disorder was initially thought to follow a benign evolution 
concerning the kidney, it was later recognized that progression to End-
Stage Renal Disease (ESRD) occurs in up to 10 percent of patients as 
natural course of the disease [2]. 
The detection and prognosis of ATTR nephropathy depend 
on the presence of albuminuria and an elevated serum creatinine 
concentration. These are correlated with the amount of amyloid in the 
glomeruli, arterioles, and medium vessels. When amyloid is confined 
to the tubulointerstitium or vasculature, proteinuria is minimal and 
reduced Glomerular Filtration Rate (GFR) is the principal clinical 
manifestation. In some patients, proximal tubular epithelial cells 
contained reabsorption-like droplets TTR positive and Congo-red 
stain negative, but clinical expression of tubular dysfunction has not 
been described until now [2]. 
Conventional measurements of renal function, such as creatinine 
and BUN levels, are limited by several non-renal factors, including body 
weight and nutritional status, which are particularly relevant in this 
population. Of special note, increased concentrations of albuminuria 
among patients with a GFR >60 ml/min (an area of weakness for serum 
creatinine and GFR), may define a higher risk patients to develop 
clinical nephropathy.
Specific urinary biomarkers for tubular and interstitial pathologic 
abnormalities are needed for early detection and timely treatment. 
Ideally, there should be early markers of nephropathy in initial stages 
of ATTR, even before neurological manifestations.
Although Orthotopic Liver Transplantation (OLT) is performed 
as a potential curative treatment, new strategies have been developed 
to treat Familial Amyloidotic Polyneuropathy (FAP) [3]. Tafamidis 
was approved for the treatment of ATTR in adult patients with 
stage 1 symptomatic polyneuropathy to delay peripheral neurologic 
impairment [4]. Several trials, some already completed and others 
recruiting participants, are evaluating new drugs [5]. Until now, trials 
did not clarify whether kidney disease is a criterion for excluding 
or adopting the use of a given drug. Most trials accept patients with 
evidence of neuropathy, some with cardiomyopathy but none of 
them have admitted patients with nephropathy as an isolated feature. 
It is questionable whether a patient with proteinuria, renal amyloid 
deposition identified as TTR and without other manifestations of 
disease would be a candidate for any future therapy.
In the past decades, several urinary proteins have been identified 
as early prognostic markers in different kidney diseases [6]. Beta-2-
Microglobulin (B2M) and Alpha-1-Microglobulin (A1M) are both 
low molecular weight proteins that are freely filtered by glomerulus, 
efficiently reabsorbed and catabolized by proximal tubule. No active 
tubular secretion or significant extra renal elimination occurs. 
Therefore, in the presence of renal dysfunction, B2M and A1M serum 
levels are increased when compared to those patients with normal 
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renal function [7]. Alpha-2 Macroglobulin (A2M) is a tetrameric 
glycoprotein, produced in human plasma that has a molecular mass of 
725 kDa [8]. Urinary levels of A2M increase when glomerular leakage 
occurs and, consequently, can act as a marker of such impairment. The 
aim of this study was to evaluate urinary A1M, B2M and A2M as early 
markers of ATTR nephropathy and predictors of outcome of renal 
disease. 
Patients and Methods
We evaluated a cohort of thirty patients and eleven asymptomatic 
gene carriers with the TTR V30M mutation. Information about 
demographics and clinical characteristics was collected. Age-at-onset 
of FAP was defined as the age of initial neurologic features.
Amyloid deposition was confirmed histologically in 24 patients; 
sections from formalin-fixed, paraffin-embedded biopsy specimens 
were stained with Congo red and viewed under cross-polarized light.
Patients who attended our clinic were followed by the same 
nephrological team. Diabetic patients and patients submitted to OLT, 
therapy with tafamidis or under any therapeutic clinical trial were 
excluded. 
Markers Measurements
On the day of the urine sample collection, blood samples were 
taken.
Serum and urinary creatinine levels (mg/dL) were measured by 
a rate-blanked compensated Jaffé method on a Modular P analyzer 
(Roche Diagnostics, Mannheim, Germany). Urinary albumin levels 
(mg) were measured with an automated immunoturbidimetric assay 
using the Cobas Integra 800 analyser (Roche Diagnostics, Mannheim, 
Germany). The amount of albuminuria was estimated by the albumin 
to creatinine ratio (mg/g). Albuminuria <30 mg/g was considered 
normal.
Urinary B2M (ng/mL) was measured by a chemiluminescent 
immunometric assay using IMMULITE 2000 (Siemens Medical 
Solutions, Erlangen, Germany), whereas urinary A1M levels (mg/L) 
and urinary A2M (mg/L) were measured with nephelometry on a 
Siemens BNII nephelometer (Siemens Medical Solutions, Erlangen, 
Germany). 
Urinary values of A1M >12 mg/L, A2M >9.4 mg/L and B2M >300 
ng/mL were considered abnormal. These biomarkers were corrected 
for urinary creatinine.
The GFR was estimated by serum cystatin C (CysC) expressed 
in mg/dL. It was determined on a nephelometric analyzer (Behring 
Nephelometer 2; Paris La Défense Cedex, Paris, France) by means 
of particle-enhanced immunonephelometry (N latex CysC; Dade 
Behring, Marburg, Germany) after calibration and control. Cystatin-
estimated GFR was calculated according to Larsson formula: GFR = 
77.239 x CysC-1.2623 [9].
The inflammatory state was evaluated by determination of 
C-reactive protein (CRP) (reference value <5 mg/L) and ferritin values 
(reference range 12.5-454 ng/mL). Pro-B-type natriuretic peptide (pro- 
BNP) concentration was measured in all subjects (reference value < 227 
pg/mL).
Statistical Analysis
Correlations were assessed by Spearman correlation coefficient 
test. The level of significance was considered to be P<0.05. Values are 
expressed as mean ± standard deviation.
Results
Patients were 49.4 ± 12.6 years-old, 18 females and 12 males, who 
presented a neuropathy evolution of 5.0 ± 4.4 years. Asymptomatic 
gene carriers were 41.4 ± 15 years-old, 9 females and 2 males.
Twenty four patients were biopsied and deposition of amyloid was 
demonstrated in 21: 15 (71.4%) on salivary gland biopsy, 4 (19%) on 
renal biopsy (Figure 1), 1 (4.8%) on myocardial tissue biopsy and 1 
(4.8%) from peripheral nerve tissue biopsy.
The laboratory data is summarized in Tables 1, 2 and 3. Eleven 
patients showed overt renal failure, with 5 of them progressing to 
dialysis. None of the patients showed glycosuria.
B2M was detected in all asymptomatic gene carriers with a mean 
value of 62.7 ng/mL (range 16.1 to 121 ng/mL). Also, A1M was present 
in 4 subjects with a mean value of 9.7 mg/L (range 8.5-12 mg/L) and 
A2M was only detected in one individual with a value of 3.34 mg/L. All 
values were on the reference range.
Pathological urinary A1M, B2M and A2M levels were detected in 
17, 6 and 5 patients respectively. However, none of the asymptomatic 
gene carriers showed such abnormal excretion.
A1M concentration was 45.2 ± 41.3 mg/L in all 30 patients. Medium 
B2M and A2M concentration were 22592.8 ± 27047.6 ng/mL and 28.6 
± 34.3 mg/L, respectively. The values corrected for urinary creatinine 
were 86 ± 110 mg/L, 54759 ± 63665 ng/mL and 56 ± 75 mg/L for each 
marker respectively.
Six patients had albuminuria <30 mg/g, 4 between 30 and 300 mg/g 
and 20 >300 mg/g. Among normoalbuminuric patients we found one 
with urinary pathological levels of A2M and A1M and another with 
abnormal B2M levels. Among 14 patients who evolved to ESRD, 5 
presented simultaneous detection of A1M and A2M.
A1M and B2M, were positively correlated with albuminuria, serum 
creatinine and cystatin C (Table 4) in all patients. A2M was almost 
exclusively found in the presence of albuminuria >30 mg/g, although 
their levels do not correlate with the severity of albuminuria. 
There were no significant correlations between urinary levels of 
A1M, B2M and A2M and pro-BNP, CRP and ferritin levels.
Figure 1: Anti-TTR fixation showed droplets accumulation in the renal proximal 
tubular cells, ATTR V30M-amyloidosis, immunoperoxidase technique, original 
magnification x400.
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Discussion
In current clinical practice, definitive diagnosis of ATTR 
nephropathy is based on renal biopsy findings. In our experience, 
however, the diagnosis can be reliably made in patients with 
albuminuria in the unequivocal presence of neuropathy. Conversely, 
we face two constraints. The first is that albuminuria is not a marker of 
tubulointerstitial damage. The second refers to the fact that this marker 
is absent in 10 percent of the patients who progress to ESRD [10].
Thus, improved methods for detect onset of kidney amyloid 
deposits, even before clinical disease, are needed to allow earlier 
treatment. This study is the first description of the contribution of 
urinary proteins, other than albumin, as non-invasive and cost-
effective markers to anticipate renal TTR amyloidosis.
A low content of protein in the urine, readily determinable, offers 
advantage over current biofluids widely used such as serum and plasma. 
The urine proteome represents the integrated product of glomerular 
filtration of plasma and protein shedding by cells of the proximal renal 
tubule, suggestive of both systemic and local contributions [11].
In our study, concentrations of all 3 urinary biomarkers increased 
progressively with decreasing GFR. One third of our patients presented 
a clear glomerular proteinuria, although significant tubular component 
was also observed. Urinary excretion of low-molecular proteins A1M 
and B2M, which are reliable indicators of tubular impairment, was 
present in 60 percent of patients. The occurrence of low molecular 
weight proteinuria, despite the absence of typical tubular syndrome, 
can be explained by the fact that megalin, a multiligand receptor 
expressed on the renal proximal tubules, functions as a specialized 
chaperone protein for internalization and degradation of a number of 
proteins, including A1M e B2M [12]. We speculate that the mechanism 
for low molecular weight proteinuria is not tubular damage but rather 
a saturation of the megalin-mediated endocytosis. So, the protein 
overload present in the lumen of the proximal tubule results in a 
combined low and high molecular weight proteinuria. We presume 
that urinary excretion of tubular proteins is related with severity of 
kidney injury and it is not a precocious marker.
The progressive dysfunction of the glomerular barrier leads to 
nonselective waste of high molecular weight proteins. Excretion of 
A2M is considered to be related with the severity of albuminuria. 
Unexpectedly, this correlation was not found. 
Tencer et al. reported the proteinuria selectivity index as useful to 
describe changes of the glomerular permeability for macromolecules 
in glomerular diseases [13]. Proteins the size of A2M cannot normally 
pass the glomerular barrier. Based on a comparison of the clearance 
of high-molecular-weight proteins to that of albumin, the pattern of 
glomerular proteinuria may be described as either selective or non-
selective. Early in the course of diabetic glomerular disease, selective 
proteinuria in both micro- and macroalbuminuric stages is observed. 
As the disease progresses, proteinuria becomes more nonselective and 
those with selective proteinuria tend to have a better outcome.
We consider that probably the low number of patients with 
pathological elimination of A2M did not allow a significant correlation.
However, the combined excretion of low and high molecular 
weight proteins was exclusively found in patients who progressed to 
ESRD.
Therefore, periodic screening of subclinical tubulopathy using 
Patients (n = 30) Asymptomatic gene carriers (n = 11)
uAlb (mg/g) 1663.9 ± 2019.9 11.5 ± 14.1
Cr (mg/dL) 1.71 ± 2.17 0.72  ± 0.14
CysC (mg/dL) 1.54 ± 1.15 0.66  ±  0.12
GFR (mL/min) 76.9 ± 52.6 137.4  ±  32.5
CRP (mg/L) 4.8 ± 10.4 3.8 ± 5.3
Ferritin (ng/mL) 190 ± 184 171 ± 228
pro-BNP (pg/mL) 1064 ± 2165 59 ± 48
Values expressed as means ± standard deviation
uAlb: albuminuria; Cr: serum creatinine; CysC: serum cystatin; GFR: glomerular filtration rate estimated by serum cystatin C; CRP: C- reactive protein; pro-BNP: pro-brain 
natriuretic peptide
Table 1: Study population laboratory parameters.
Gender Age uAlb Cr CysC GFR B2M A1M A2M CRP Ferritin pro-BNP
M 63 21,1 0,96 0,87 91 28,7 8,5 <2,53 1,42 278 34,2
F 37 3,2 0,53 0,48 201 104 <5,16 <2,41 0,83 50 26,7
M 63 3,5 0,89 0,85 93 18,9 <5,96 <2,41 2,91 821 36,7
F 28 4,6 0,82 0,62 141 16,1 <5,16 <2,41 3,37 60 25,7
F 30 16,7 0,5 0,54 171 74,1 <5,96 <2,41 1,23 127 58,7
F 33 2 0,72 0,65 134 121 <5,96 <2,41 18,39 90 42,6
F 30 11 0,74 0,61 144 20,9 <5,16 <2,41 2,18 166 41
F 27 0,9 0,78 0,64 136 91,3 <5,96 <2,41 1,58 49 71,3
F 33 7,1 0,66 0,57 160 72 12 3,34 8,34 152 198,1
F 63 7,4 0,7 0,73 114 43,7 8,86 <2,41 0,76 37 56,9
F 48 49,5 0,65 0,67 127 98,9 9,21 <2,47 0,75 47 55,6
M- male; F- female
uAlb: albuminuria (mg/g); Cr: serum creatinine (mg/dL); CysC: serum cystatin (mg/dL); GFR: glomerular filtration rate estimated by serum cystatin C (mL/min); B2M: 
beta-2 microglobulin (ng/ml); A1M: alpha-1 microglobulin (mg/L); A2M: alpha-2 macroglobulin (mg/L); CRP: C- reactive protein (mg/L); ferritin (ng/mL); pro-BNP: pro-brain 
natriuretic peptide (pg/mL).
Table 2: Laboratory assessment in asymptomatic gene carriers.
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these urinary biomarkers appears to be a simple and non-invasive 
means of identifying ATTR patients at risk of kidney disease, including 
impeding decline in kidney function.
Vyssouli et al. in a study involving 1445 nondiabetic patients 
revealed that urinary A1M is independently associated with circulating 
acute phase proteins in patients with newly diagnosed hypertension. 
They concluded that urinary A1M may reflect the overall inflammatory 
status in patients with newly diagnosed hypertension, beyond its value 
as a marker of renal function [14]. In order to exclude the variation 
associated with inflammatory markers we evaluated CRP and ferritin. 
None of the individuals presented abnormal values. We did not find a 
correlation between A1M and these inflammatory proteins.
Cardiomyopathy is another well-known complication in FAP. 
Considering that pro-BNP appears to be a sensitive marker for heart 
complications and proved valuable for follow-up purposes [15], 
we decided to search for a correlation between cardiac and kidney 
biomarkers. Nonetheless, no significant relation was found for this 
sample.
It must be highlighted that our study design has some limitations, 
such as the small size of the sample and the lack of a gold standard 
method to evaluate GFR. Additionally, we only had single measurements 
of B2M, A1M, A2M, CysC, and creatinine, and these measurements are 
known to vary within participants.
Actually, an encouraging source of molecular markers for renal 
dysfunction and structural injury is urinary exosomes, nanovesicles 
released by renal epithelial cells including glomerular podocytes, renal 
Gender Age uAlb Cr CysC GFR B2M A1M A2M CRP Ferritin pro-BNP
M 64 5,9 1,27 1,25 56 4,29 <5,69 <2,47 3,39 158 256,6
F 62 78,9 0,69 1,07 68 5,22 6,6 <2,47 2,8 453 1643
M 59 1877,8 1,12 0,842 94 5,69 24,3 2,6 1,43 95 155,9
F 52 1762,5 1,46 1,51 43 12,9 32,5 14,7 0,83 128 169,3
M 38 680,5 1,52 1,71 37 15,16 34,4 <2,53 7,96 326 134
F 55 4222,2 0,91 1,15 62 18,4 26,6 5,29 1,07 70 323,7
F 32 1192,7 0,47 0,497 190 25,7 6,46 <2,41 0,37 45 81,4
F 44 671 0,65 0,843 94 25,7 25,7 3,6 0,39 143 131,8
F 41 4187,1 0,54 0,96 79 28,2 9,16 <2,47 0,14 13 91,6
F 43 1298,4 0,63 1,07 68 31,2 41,2 <2,41 53,46 38 594,9
M 43 152,8 0,87 1,29 53 43,2 6,99 <2,41 26,35 91
F 71 5103,3 4,56 3,76 13 46,13 123 17 1,87 490 2657
F 34 8,4 0,76 0,75 110 55,3 6,29 <2,47 4 57 196
F 69 676 0,78 1,33 51 59,7 8,22 <2,47 4,05 322 239,9
M 50 67,9 0,76 0,63 138 59,9 10,2 <2,47 2,6 553 16,6
F 39 696,2 0,35 0,47 204 63 15,5 <2,47 1,97 19 171
M 32 3,7 0,87 0,69 122 74,3 6,61 <2,41 0,51 18 16,3
M 56 83,2 0,81 0,66 130 84,7 <5,96 <2,47 3,45 110 81,7
F 48 642,5 0,52 0,85 93 105 14,2 <2,41 0,84 18 144,7
M 40 577 2,94 2,91 18 117 47,6 2,5 0,19 45 1076
F 39 6,2 0,63 0,64 135 119 <5,16 <2,41 0,27 122 134,5
F 46 2,9 0,59 0,67 128 127 13,7 6,3 0,59 91 40,2
M 36 790 0,58 0,79 103 173 16,5 4,35 2,2 288 174,8
F 52 2381,7 1,43 2,86 18 297 9,34 <2,47 10,32 244 4205
M 28 6,8 0,73 0,76 107 327 7,36 <2,47 0,76 271 20,6
M 64 1989 1,56 1,78 35 784 25,3 10 2,32 482 646,7
M 49 3193,3 1,98 2,95 18 6592 37,3 4,93 4,03 68 1712
F 60 4728,7 6,17 3,19 16 26122 158 11,3 2,89 47 904,4
F 69 7526,9 4,82 3,79 13 30627 98,5 4,85 1,89 204 4216
F 68 5303,8 10,45 4,65 10 71105 34,8 89,8 0,68 691 10616
M- male; F- female
uAlb: albuminuria (mg/g); Cr: serum creatinine (mg/dL); CysC: serum cystatin (mg/dL); GFR: glomerular filtration rate estimated by serum cystatin C (mL/min); B2M: 
beta-2 microglobulin (ng/ml); A1M: alpha-1 microglobulin (mg/L); A2M: alpha-2 macroglobulin (mg/L); CRP: C- reactive protein (mg/L); ferritin (ng/mL); pro-BNP: pro-brain 
natriuretic peptide (pg/mL)
Table 3: Laboratory assessment in patients.
A1M A1M/cr B2M B2M/cr
Variables R P Value R P Value R P Value R P Value
uAlb 0.68 <0.01 0.79 <0.001 0.71 <0.01 0.66 <0.01
Cr 0.57 <0.05 0.71 <0.01 0.74 <0.001 0.69 <0.01
CysC 0.70 <0.001 0.76 <0.001 0.65 <0.01 0.58 <0.01
uAlb: albuminuria; Cr: serum creatinine; CysC: serum cystatin
Table 4: Correlations between alpha 1-microglobulin (A1M) and beta-2 microglobulin (B2M).
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tubule cells and the cells lining the ureter and bladder [16]. When 
combined with mass spectrometry and other proteomics techniques, 
urinary exosomes provide an opportunity to study proteins that were 
once either difficult or impossible to reach. For amyloidosis a first 
approach was designed in light chain amyloidosis [17]. 
However, it should be noted the fact that several proteins were 
evaluated together in the same population.
It is likely that a combination of biomarkers will be required for 
assessing disease detection and future response to a treatment. In 
conclusion, the use of urinary low and high molecular weight proteins, 
like A1M, B2M and A2M, represented useful markers to estimate 
injury severity and monitoring the progression of renal lesion in ATTR 
V30M. The design of clinical urinary proteomics studies may increase 
our understanding of renal involvement in ATTR in the near future.
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